

# Stephen P Mulligan

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8104259/publications.pdf>

Version: 2024-02-01

80  
papers

4,278  
citations

304368

22  
h-index

114278

63  
g-index

83  
all docs

83  
docs citations

83  
times ranked

4205  
citing authors

#	ARTICLE	IF	CITATIONS
1	COVID-19 vaccine failure in chronic lymphocytic leukaemia and monoclonal B-lymphocytosis; humoral and cellular immunity. <i>British Journal of Haematology</i> , 2022, 197, 41-51.	1.2	32
2	Immunoglobulin replacement therapy in chronic lymphocytic leukaemia patients with hypogammaglobulinaemia and infection. <i>European Journal of Haematology</i> , 2022, 108, 460-468.	1.1	2
3	Second primary malignancies in chronic lymphocytic leukaemia: Skin, solid organ, haematological and Richter's syndrome. <i>EJHaem</i> , 2022, 3, 129-138.	0.4	10
4	Ibrutinib use, treatment duration, and concomitant medications in Australian patients with relapsed or refractory chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2022, 198, 790-793.	1.2	4
5	Monoclonal B-cell Lymphocytosis "a review of diagnostic criteria, biology, natural history, and clinical management. <i>Leukemia and Lymphoma</i> , 2022, 63, 2795-2806.	0.6	3
6	The ClpP activator ONC212 (TR31) inhibits BCL2 and B-cell receptor signaling in CLL. <i>EJHaem</i> , 2021, 2, 81-93.	0.4	4
7	COVID-19 vaccination in haematology patients: an Australian and New Zealand consensus position statement. <i>Internal Medicine Journal</i> , 2021, 51, 763-768.	0.5	12
8	Measurable residual disease in chronic lymphocytic leukemia: expert review and consensus recommendations. <i>Leukemia</i> , 2021, 35, 3059-3072.	3.3	40
9	Using ibrutinib in earlier lines of treatment results in better outcomes for patients with chronic lymphocytic leukemia/small lymphocytic lymphoma. <i>Leukemia and Lymphoma</i> , 2021, 62, 3278-3282.	0.6	7
10	IBL-202 is synergistic with venetoclax in CLL under in vitro conditions that mimic the tumor microenvironment. <i>Blood Advances</i> , 2020, 4, 5093-5106.	2.5	4
11	Ibrutinib restores immune cell numbers and function in first-line and relapsed/refractory chronic lymphocytic leukemia. <i>Leukemia Research</i> , 2020, 97, 106432.	0.4	40
12	A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenström macroglobulinemia: the ASPEN study. <i>Blood</i> , 2020, 136, 2038-2050.	0.6	281
13	Zanubrutinib for the treatment of MYD88 wild-type Waldenström macroglobulinemia: a substudy of the phase 3 ASPEN trial. <i>Blood Advances</i> , 2020, 4, 6009-6018.	2.5	57
14	Australian and New Zealand consensus statement on the management of lymphoma, chronic lymphocytic leukaemia and myeloma during the COVID-19 pandemic. <i>Internal Medicine Journal</i> , 2020, 50, 667-679.	0.5	37
15	Managing haematology and oncology patients during the COVID-19 pandemic: interim consensus guidance. <i>Medical Journal of Australia</i> , 2020, 212, 481-489.	0.8	107
16	Therapeutic approaches and drug-resistance in chronic lymphocytic leukaemia. , 2020, 3, 532-549.		0
17	Molecular pathogenesis of chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2019, 186, 668-684.	1.2	12
18	Final analysis from RESONATE: Up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma. <i>American Journal of Hematology</i> , 2019, 94, 1353-1363.	2.0	305

#	ARTICLE	IF	CITATIONS
19	Ibrutinib-associated invasive fungal diseases in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: An observational study. <i>Mycoses</i> , 2019, 62, 1140-1147.	1.8	57
20	Chronic lymphocytic leukemia, skin and other second cancers. <i>Leukemia and Lymphoma</i> , 2019, 60, 3104-3106.	0.6	9
21	Long-term follow-up of the RESONATE phase 3 trial of ibrutinib vs ofatumumab. <i>Blood</i> , 2019, 133, 2031-2042.	0.6	178
22	Prognostic value of MRD in CLL patients with comorbidities receiving chlorambucil plus obinutuzumab or rituximab. <i>Blood</i> , 2019, 133, 494-497.	0.6	32
23	Dual inhibition of MEK1/2 and AKT by binimetinib and MK2206 induces apoptosis of chronic lymphocytic leukemia cells under conditions that mimic the tumor microenvironment. <i>Leukemia and Lymphoma</i> , 2019, 60, 1632-1643.	0.6	7
24	Final analysis from RESONATE: Six-year follow-up in patients (pts) with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) on ibrutinib. <i>Journal of Clinical Oncology</i> , 2019, 37, 7510-7510.	0.8	1
25	Using Ibrutinib in Earlier Lines of Treatment Results in Better Outcomes for Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. <i>Blood</i> , 2019, 134, 3054-3054.	0.6	2
26	Humoral immune failure defined by immunoglobulin class and immunoglobulin G subclass deficiency is associated with shorter treatment-free and overall survival in Chronic Lymphocytic Leukaemia. <i>British Journal of Haematology</i> , 2018, 181, 97-101.	1.2	36
27	Ibrutinib and idelalisib block immunophenotypic changes associated with the adhesion and activation of CLL cells in the tumor microenvironment. <i>Leukemia and Lymphoma</i> , 2018, 59, 1927-1937.	0.6	8
28	Recommendations for skin cancer monitoring for patients with chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2018, 59, 578-582.	0.6	12
29	Venetoclax for Patients With Chronic Lymphocytic Leukemia With 17p Deletion: Results From the Full Population of a Phase II Pivotal Trial. <i>Journal of Clinical Oncology</i> , 2018, 36, 1973-1980.	0.8	257
30	MEK1/2 inhibition by binimetinib is effective as a single agent and potentiates the actions of Venetoclax and ABT-737 under conditions that mimic the chronic lymphocytic leukaemia (CLL) tumour microenvironment. <i>British Journal of Haematology</i> , 2018, 182, 360-372.	1.2	23
31	The dual inhibitor of the phosphoinositol-3 and PIM kinases, IBL-202, is effective against chronic lymphocytic leukaemia cells under conditions that mimic the hypoxic tumour microenvironment. <i>British Journal of Haematology</i> , 2018, 182, 654-669.	1.2	12
32	Inhibition of the Raf-1 kinase inhibitory protein (RKIP) by locostatin induces cell death and reduces the CXCR4-mediated migration of chronic lymphocytic leukemia cells. <i>Leukemia and Lymphoma</i> , 2018, 59, 2917-2928.	0.6	13
33	Immune failure, infection and survival in chronic lymphocytic leukemia. <i>Haematologica</i> , 2018, 103, e329-e329.	1.7	18
34	Improvement in Parameters of Hematologic and Immunologic Function and Patient Well-being in the Phase III RESONATE Study of Ibrutinib Versus Ofatumumab in Patients With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, 803-813.e7.	0.2	32
35	Ibrutinib Treatment Improves T-Cell Proliferative Ability and Effector Function in Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) Patients. <i>Blood</i> , 2018, 132, 3114-3114.	0.6	1
36	Impact of ibrutinib dose adherence on therapeutic efficacy in patients with previously treated CLL/SLL. <i>Blood</i> , 2017, 129, 2612-2615.	0.6	111

#	ARTICLE	IF	CITATIONS
37	Successful use of Bruton's kinase inhibitor, ibrutinib, to control paraneoplastic pemphigus in a patient with paraneoplastic autoimmune multiorgan syndrome and chronic lymphocytic leukaemia. <i>Australasian Journal of Dermatology</i> , 2017, 58, e240-e242.	0.4	30
38	Modeling the chronic lymphocytic leukemia microenvironment <i>in vitro</i> . <i>Leukemia and Lymphoma</i> , 2017, 58, 266-279.	0.6	18
39	Long-term efficacy and safety with ibrutinib (ibr) in previously treated chronic lymphocytic leukemia (CLL): Up to four years follow-up of the RESONATE study.. <i>Journal of Clinical Oncology</i> , 2017, 35, 7510-7510.	0.8	11
40	Hematology oncology practice in the Asia-Pacific APHCON survey results from the 6th international hematologic malignancies conference: bridging the gap 2015, Beijing, China. <i>Oncotarget</i> , 2017, 8, 41620-41630.	0.8	1
41	Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study. <i>Lancet Oncology</i> , The, 2016, 17, 768-778.	5.1	676
42	Atrial fibrillation, anticoagulant stroke prophylaxis and bleeding risk with ibrutinib therapy for chronic lymphocytic leukaemia and lymphoproliferative disorders. <i>British Journal of Haematology</i> , 2016, 175, 359-364.	1.2	25
43	Serum from a subset of patients with chronic lymphocytic leukemia and large local reactions to mosquito bites induces upregulation of CD63 surface expression on basophils in atopic donors. <i>Leukemia and Lymphoma</i> , 2016, 57, 2417-2420.	0.6	3
44	Protein profiles distinguish stable and progressive chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2016, 57, 1033-1043.	0.6	8
45	Outcomes of Ibrutinib Therapy By Age in Patients with CLL/SLL: Analyses from Phase 3 Trial Data (RESONATE and RESONATE-2). <i>Blood</i> , 2016, 128, 2041-2041.	0.6	4
46	Interim Analysis of Lenalidomide Consolidation on Minimal Residual Disease in Patients with Chronic Lymphocytic Leukemia Following Initial FCR Chemotherapy - CLL6 Residuum Study of the Australian Leukaemia and Lymphoma Group (ALLG) and the French Innovative Leukemia Organization (FILO). <i>Blood</i> , 2016, 128, 2053-2053.	0.6	3
47	Ofatumumab and its role as immunotherapy in chronic lymphocytic leukemia. <i>Haematologica</i> , 2015, 100, 411-414.	1.7	15
48	The MEK1/2 inhibitor, MEKi-1, induces cell death in chronic lymphocytic leukemia cells under conditions that mimic the tumor microenvironment and is synergistic with fludarabine. <i>Leukemia and Lymphoma</i> , 2015, 56, 3407-3417.	0.6	15
49	Monoclonal B-lymphocytosis in patients aged over 90 years is common but not inevitable, and has a prevalence comparable to that in individuals aged 65-90 years. <i>Leukemia and Lymphoma</i> , 2015, 56, 2182-2184.	0.6	3
50	Chronic lymphocytic leukaemia, monoclonal B-lymphocytosis and pregnancy: five cases, a literature review and discussion of management. <i>British Journal of Haematology</i> , 2015, 168, 350-360.	1.2	17
51	Reproducible Diagnosis of Chronic Lymphocytic Leukemia (CLL) By Flow Cytometry: An European Research Initiative on CLL (ERIC) & European Society for Clinical Cell Analysis (ESCCA) Harmonisation Project. <i>Blood</i> , 2015, 126, 4146-4146.	0.6	2
52	Venetoclax (ABT-199/GDC-0199) Monotherapy Induces Deep Remissions, Including Complete Remission and Undetectable MRD, in Ultra-High Risk Relapsed/Refractory Chronic Lymphocytic Leukemia with 17p Deletion: Results of the Pivotal International Phase 2 Study. <i>Blood</i> , 2015, 126, LBA-6-LBA-6.	0.6	13
53	Dose adherence and baseline exposure analysis of the ibrutinib 420 mg dose administered to patients with previously treated chronic lymphocytic leukemia (CLL).. <i>Journal of Clinical Oncology</i> , 2015, 33, 7012-7012.	0.8	3
54	Targeting chronic lymphocytic leukemia cells in the tumor microenvironment: A review of the <i>in vitro</i> and clinical trials to date. <i>World Journal of Clinical Cases</i> , 2015, 3, 694.	0.3	8

#	ARTICLE	IF	CITATIONS
55	The Hsp90 inhibitor SNX-7081 is synergistic with fludarabine nucleoside via DNA damage and repair mechanisms in human, p53-negative chronic lymphocytic leukemia. <i>Oncotarget</i> , 2015, 6, 40981-40997.	0.8	9
56	Clostridium Difficile Infection in Haematology Patients Significantly Increases Length of Stay; A Case Control Study. <i>Blood</i> , 2015, 126, 2108-2108.	0.6	0
57	Quality of Life in Fit Elderly Patients with Chronic Lymphocytic Leukemia (CLL) Receiving Oral Fludarabine-Based Regimens As First Line Therapy: Australasian Leukaemia and Lymphoma Group (ALLG) CLL5 Trial. <i>Blood</i> , 2015, 126, 5295-5295.	0.6	0
58	Interim Positron Emission Tomography-Computed Tomography (PET-CT) Is Predictive of Post-Therapy Outcome in High Grade Transformation of Low Grade Lymphoproliferative Disorders. <i>Blood</i> , 2015, 126, 5038-5038.	0.6	0
59	Risk Stratification Combining MYC Immunohistochemistry with Standard IPI Has Utility in Patients with Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2015, 126, 2656-2656.	0.6	0
60	Cladribine prolongs progression-free survival and time to second treatment compared to fludarabine and high-dose chlorambucil in chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2014, 55, 2769-2777.	0.6	9
61	Modelling the Cost Effectiveness of Rituximab in Chronic Lymphocytic Leukaemia in First-Line Therapy and Following Relapse. <i>Pharmacoeconomics</i> , 2014, 32, 193-207.	1.7	20
62	Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia. <i>New England Journal of Medicine</i> , 2014, 371, 213-223.	13.9	1,427
63	The Oxazolidinone Derivative Locostatin Induces Apoptosis in CLL Cells through Inhibition of AKT and MAPK-ERK1/2 Signaling Under Conditions That Mimic the Tumor Microenvironment. <i>Blood</i> , 2014, 124, 3326-3326.	0.6	2
64	Updated Efficacy Including Genetic and Clinical Subgroup Analysis and Overall Safety in the Phase 3 RESONATE™ Trial of Ibrutinib Versus Ofatumumab in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. <i>Blood</i> , 2014, 124, 3331-3331.	0.6	24
65	Toxicity Is Not Associated with Age or Comorbidity Score in a Randomised Study of Oral Fludarabine and Cyclophosphamide and IV Rituximab (FCR) As First-Line Therapy of Fit, Elderly Patients with Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2014, 124, 4695-4695.	0.6	5
66	Hematologic and Immunologic Function and Patient Well-Being for the Phase III RESONATE™ Study of Ibrutinib Vs Ofatumumab in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. <i>Blood</i> , 2014, 124, 4696-4696.	0.6	12
67	Autoimmune Hemolytic Anemia and Immune Mediated Thrombocytopenia in the Phase III RESONATE™ Study of Ibrutinib Vs Ofatumumab in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Including a Case Report. <i>Blood</i> , 2014, 124, 5654-5654.	0.6	13
68	Randomized comparison of ibrutinib versus ofatumumab in relapsed or refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma: Results from the phase III RESONATE trial.. <i>Journal of Clinical Oncology</i> , 2014, 32, LBA7008-LBA7008.	0.8	2
69	Randomized comparison of ibrutinib versus ofatumumab in relapsed or refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma: Results from the phase III RESONATE trial.. <i>Journal of Clinical Oncology</i> , 2014, 32, LBA7008-LBA7008.	0.8	5
70	A Complementary Role of High Throughput Sequencing and Multiparameter Cytometry for Minimal Residual Disease (MRD) Detection in Chronic Lymphocytic Leukemia (CLL):an European Research Initiative (ERIC) Study. <i>Blood</i> , 2014, 124, 1976-1976.	0.6	2
71	Immunoglobulin G subclass deficiency and infection risk in 150 patients with chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2013, 54, 99-104.	0.6	89
72	Monoclonal B-lymphocytosis: reflections and definitions. <i>Leukemia and Lymphoma</i> , 2012, 53, 1647-1650.	0.6	3

#	ARTICLE	IF	CITATIONS
73	Inhibition of Mitogen Activated Protein Kinase Kinase (MEK1) Is Effective Against CLL Cells Cultured in Media Alone or in a Supportive Microenvironment and Is Synergistic with Fludarabine in a Mechanism That Involves Decreased Levels of Reactive Oxygen Species and MCL-1 Protein. <i>Blood</i> , 2012, 120, 1804-1804.	0.6	0
74	A Randomised Dose De-Escalation Safety Study of Oral Fludarabine, ±Oral Cyclophosphamide and Intravenous Rituximab (OFOCIR) As First-Line Therapy of Fit Patients with Chronic Lymphocytic Leukaemia (CLL) Aged ≥65 Years – End of Recruitment Analysis of Response and Toxicity of the Australasian Leukaemia and Lymphoma Group (ALLG) and CLL Australian Research Consortium (CLLARC) CLL5 Study. <i>Blood</i> , 2012, 120, 436-436.	0.6	6
75	Monoclonal B-lymphocytosis: demographics, nature and subclassification in 414 community patients. <i>Leukemia and Lymphoma</i> , 2011, 52, 2293-2298.	0.6	15
76	The Safety and Tolerability of Oral Fludarabine, ±oral Cyclophosphamide and Iv Rituximab Therapy In Previously Untreated Patients with Chronic Lymphocytic Leukaemia (CLL) Aged ≥65 Years – Interim Analysis From the Australasian Leukaemia and Lymphoma Group (ALLG) and CLL Australian Research Consortium (CLLARC) CLL5 Study.. <i>Blood</i> , 2010, 116, 699-699.	0.6	4
77	Monoclonal B-Lymphocytosis: Analysis of the Incidence, Demographics, Nature and Subclassification in 414 Patients. <i>Blood</i> , 2008, 112, 3129-3129.	0.6	1
78	Immunoglobulin G (IgG) Subclasses in Chronic Lymphocytic Leukaemia. <i>Blood</i> , 2008, 112, 4180-4180.	0.6	0
79	Chronic lymphocytic leukaemia resistant to both fludarabine and alemtuzumab – Double jeopardy. <i>Leukemia and Lymphoma</i> , 2007, 48, 1885-1887.	0.6	1
80	Cladribine (CdA) Gives Longer Response Duration Than Fludarabine (F) and High-Dose Intermittent Chlorambucil (Chl) as First-Line Treatment of Symptomatic Chronic Lymphocytic Leukemia (CLL). First Results from the International Randomized Phase III Trial.. <i>Blood</i> , 2007, 110, 630-630.	0.6	6